T
Timberlyne Therapeutics
Transformational therapies for autoimmune diseases with CM313, a monoclonal antibody targeting CD38 for rapid, durable responses
About Timberlyne Therapeutics
Timberlyne Therapeutics is a clinical stage biopharmaceutical company dedicated to developing and commercializing therapies for autoimmune diseases. The company leverages its team's extensive drug development expertise to acquire and apply best-in-class assets against compelling targets. Timberlyne's lead program, CM313, is an IgG1 monoclonal antibody with enhanced cytotoxicity that targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells. By targeting CD38, CM313 modulates multiple arms of the immune system, leading to rapid and durable responses across various autoimmune diseases. Timberlyne aims to develop CM313 for a broad range of autoimmune indications, addressing significant unmet medical needs. Founded in 2024, the company has raised $180 million from leading life sciences investors to advance its mission of bringing life-changing medicines to patients. Timberlyne was formed by Mountainfield Venture Partners in partnership with Keymed Biosciences and has exclusive development and commercialization rights to CM313 worldwide, excluding greater China.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- San Diego, United States
- Open positions
- None listed
- Dealroom signal
- 57.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Rumoured $1B, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jan 2025 | $180M | $720M | Boyu Capital · Lilly Asia Ventures · Braidwell · Venrock Healthcare Capital Partners | ↗ |
Growth signals
Latest recorded traffic for Timberlyne Therapeutics is 1.1K monthly website visits, down 15.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Timberlyne Therapeutics in the San Diego ecosystem
The Timberlyne Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
- VPVenrock Healthcare Capital Partners
Abingworth
Bain Capital Life Sciences
Boyu Capital
Lilly Asia Ventures
Braidwell
3H Health Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Timberlyne Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Timberlyne Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










